The company is a specialty biopharmaceutical company that utilizes an immunology-based drug development platform to actualize therapeutics indicated for cancer and autoimmune disease. The company’s methodology functions by first identifying disease specific markers, or antigens, on afflicted biological tissue, and then using these antigens to produce immune system-eliciting proteins known as antibodies. The antibodies are then introduced into patients with the particular disease, where the antibodies bind specifically to the affected tissue, inducing the patient’s immune system to establish an attack against the disease. The company has developed humanized antibodies to treat the autoimmune diseases systemic lupus erythematosus, sjogren’s syndrome, rheumatoid arthritis, as well as antibodies indicated for cancer including follicular lymphoma, chronic lymphocytic leukemia, and advanced pancreatic cancer. All of the company’s drugs are currently in advanced clinical trials.
The Cancer Consortium
Cancer News & Information Center
